Trial Profile

Clinical study of fully human anti-BCMA CAR-T cell therapy Equecabtagene autoleucel

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 21 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Equecabtagene autoleucel (Primary)
Indications Multiple myeloma; Multiple sclerosis; Myasthenia gravis; Neuromyelitis optica
Focus Adverse reactions

21 Nov 2025 New trial record
21 Oct 2025 According to Iaso Therapeutics media release, the data generated from Japan clinical study, in combination with the existing clinical data from China, can be directly submitted to support the New Drug Application (NDA).
21 Oct 2025 According to Iaso Therapeutics media release, the Clinical Trial Notification (CTN) was approved in Japan for fully human anti-BCMA CAR-T cell therapy. This implies that Japanese regulatory authorities have recognized the clinical research data it completed in China. Based on this approval, IASO Bio can conduct a small sample size clinical study in Japan.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com